YHYongpeng He

Yongpeng He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yongpeng He has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Aijuan Xie

    1 shared publication
  • Boxuan Feng

    NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China

    1 shared publication
  • Chao Peng

    Megvii Inc. (Face++)

    1 shared publication
  • Chuanning Tang

    Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases and Academician Workstation of Hainan Province, Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou 571199, China

    1 shared publication
  • Daihong Liu

    Department of Radiology, Chongqing University Cancer Hospital, School of Medicine Chongqing University Chongqing China

    1 shared publication
  • Fan Yang

    Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China

    1 shared publication

Latest Publications

  • Open Access

    Limosilactobacillus fermentum XY18 Relieves CCl 4 ‐Induced Acute Liver Injury in Mice by Antioxidant and Anti‐Inflammatory

    by Ranran Wang, Liping Yang, Aijuan Xie, Ruokun Yi, Yongpeng He, Xin Zhao, Zhaofeng Tian

    This study investigated whether Limosilactobacillus fermentum XY18 (LF‐XY18) prevents carbon tetrachloride (CCl 4 )‐induced mice acute liver injury (ALI) by alleviating oxidative stress and inflammation. LF‐XY18 reduced liver weight, improved injury indices, and alleviated histological abnormalities in mice. LF‐XY18 significantly reduced serum alanine triglycerides (TG), aspartate aminotransferase (AST), total cholesterol (TC), and aminotransferase (ALT) levels and reduced the myeloperoxidase (MPO) and malondialdehyde (MDA) concentrations in both serum and liver tissues, while increasing glutathione (GSH) and superoxide dismutase (SOD) levels in these compartments. Moreover, LF‐XY18 activated the nuclear factor‐erythroid‐2‐related‐factor‐2 (Nrf2) antioxidant pathway, upregulating heme oxygenase‐1 (HO‐1), copper‐zinc superoxide dismutase (Cu/Zn‐SOD), manganese‐superoxide dismutase (Mn‐SOD), and glutathione peroxidase (GSH‐Px). Simultaneously, LF‐XY18 modulated the nuclear factor κ‐light‐chain‐enhancer of activated B cells (NF‐κB)‐mediated inflammatory responses, restoring the NF‐κB, B‐cell inhibitor‐α (IκB‐α), neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS), inducible NOS (iNOS), and cyclooxygenase‐2 (COX‐2) expressions. LF‐XY18 dose‐dependently ameliorated CCl 4 ‐induced ALI through oxidative stress and inflammation suppression, demonstrating probiotic properties suitable for development as hepatoprotective dietary supplements.


  • Open Access

    Diversity and independent evolutionary profiling of rodent-borne viruses in Hainan, a tropical island of China

    by Youyou Li, Chuanning Tang, Yun Zhang, Zihan Li, Gaoyu Wang, Ruoyan Peng, Yi Huang, Xiaoyuan Hu, Henan Xin, Boxuan Feng, et al.

    The risk of emerging infectious diseases (EID) is increasing globally. More than 60% of EIDs worldwide are caused by animal-borne pathogens. This study aimed to characterize the virome, analyze the phylogenetic evolution, and determine the diversity of rodent-borne viruses in Hainan Province, China. We collected 682 anal and throat samples from rodents, combined them into 28 pools according to their species and location, and processed them for next-generation sequencing and bioinformatics analysis. The diverse viral contigs closely related to mammals were assigned to 22 viral families. Molecular clues of the important rodent-borne viruses were further identified by polymerase chain reaction for phylogenetic analysis and annotation of genetic characteristics such as arenavirus, coronavirus, astrovirus, pestivirus, parvovirus, and papillomavirus. We identified pestivirus and bocavirus in Leopoldoms edwardsi from Huangjinjiaoling, and bocavirus in Rattus andamanensis from the national nature reserves of Bangxi with low amino acid identity to known pathogens are proposed as the novel species, and their rodent hosts have not been previously reported to carry these viruses. These results expand our knowledge of viral classification and host range and suggest that there are highly diverse, undiscovered viruses that have evolved independently in their unique wildlife hosts in inaccessible areas.


  • Open Access

    Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma

    by Hesong Shen, Yu Wang, Daihong Liu, Rongfei Lv, Yuanying Huang, Chao Peng, Shixi Jiang, Ying Wang, Yongpeng He, Xiaosong Lan, et al.

    Objectives: This study aimed to explore the predictive value of MRI-based radiomic model for progression-free survival (PFS) in nonmetastatic nasopharyngeal carcinoma (NPC). Methods: A total of 327 nonmetastatic NPC patients [training cohort (n = 230) and validation cohort (n = 97)] were enrolled. The clinical and MRI data were collected. The least absolute shrinkage selection operator (LASSO) and recursive feature elimination (RFE) were used to select radiomic features. Five models [Model 1: clinical data, Model 2: overall stage, Model 3: radiomics, Model 4: radiomics + overall stage, Model 5: radiomics + overall stage + Epstein–Barr virus (EBV) DNA] were constructed. The prognostic performances of these models were evaluated by Harrell's concordance index (C-index). The Kaplan–Meier method was applied for the survival analysis. Results: Model 5 incorporating radiomics, overall stage, and EBV DNA yielded the highest C-indices for predicting PFS in comparison with Model 1, Model 2, Model 3, and Model 4 (training cohorts: 0.805 vs. 0.766 vs. 0.749 vs. 0.641 vs. 0.563, validation cohorts: 0.874 vs. 0.839 vs. 836 vs. 0.689 vs. 0.456). The survival curve showed that the high-risk group yielded a lower PFS than the low-risk group. Conclusions: The model incorporating radiomics, overall stage, and EBV DNA showed better performance for predicting PFS in nonmetastatic NPC patients.